Crosslinked hydrogels for tympanic membrane repair
Presented at the Annual Meeting of the American Academy of Otolaryngology–Head and Neck Surgery, Los Angeles, CA, September 14-18, 2005.
Problem
To provide a less expensive and more convenient protocol for the treatment of tympanic membrane perforations (TMPs).
Methods
Several materials were prepared and compared for TMP repair including Carbylan-SX, Gelatin-DTPH-PEGDA (GX), Carbylan-S/Gelatin-DTPH (Carbylan-GSX) (injectable and sponge), Gelfoam, Epifilm, and crosslinked thiolated chondroitin sulfate (CS-DTPH-PEGDA [CS-SX]). Hartley pigmented guinea pigs (Elm Hill) underwent bilateral myringotomy with 1 ear left as a control and the other treated with one of the previously mentioned materials.
Results
Carbylan-GSX (injectable and sponge), Gelfoam with saline, and CS-SX had the shortest time for TMP closure. Epifilm, Carbylan, and gelatin preparations resulted in closure rates similar to controls. CS-SX showed a marked inflammatory reaction compared with controls and other materials based on neutrophil, lymphocyte, epitheloid counts, and degree of fibrosis.
Conclusions
This study shows the validity of Carbylan-GSX compared with Gelfoam as a material to promote TMP closure in an acute TMP guinea pig model.
aDivision of Otolaryngology–Head and Neck Surgery, University of Utah, Salt Lake City, Utah
bCenter for Therapeutic Biomaterials, University of Utah, Salt Lake City, Utah
cDepartment of Bioengineering, University of Utah, Salt Lake City, Utah
dCommunicative Sciences and Disorders and Animal Reference Pathology, University of Utah, Salt Lake City, Utah
eDivision of Associated Regional and University Pathologists, Inc, Salt Lake City, Utah
fFamily and Preventive Medicine, University of Utah, Salt Lake City, Utah
gDepartment of Medicinal Chemistry, University of Utah, Salt Lake City, Utah
Reprint requests: Albert H. Park, MD, University of Utah School of Medicine, Division of Otolaryngology–Head and Neck Surgery, 50 North Medical Drive, 3C 120, Salt Lake City, UT 84132.
Supported by small business technology transfer research (STTR) NIH grant R41 EB004710-01 and the Utah Centers of Excellence program.
Drs Park and Prestwich are cofounders of Sentrx Surgical, Inc. Financial disclosure: Sentrx Surgical, Inc was recently purchased by Carbylan Inc. Currently, Dr. Prestwich chairs the scientific advisory panel, obtains salary from the organization, has patent ownership of the Carbylan biomaterials, is a shareholder of the company and was the principal investigator of the NIH STTR grant. Dr. Shu also has patent ownership of the Carbylan biomaterials. Dr. Park is a consultant for Carbylan, Inc. Dr. Park receives a small amount of salary support, is a shareholder and was a co-investigator for the NIH STTR grant.
ABSTRACT